共 50 条
Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity
被引:18
|作者:
Troost, Esther G. C.
[1
]
Bussink, Johan
[1
]
Slootweg, Piet J.
[2
]
Peeters, Wenny J. M.
[1
]
Merkx, Matthias A. W.
[3
]
van der Kogel, Albert J.
[1
]
Oyen, Wim J. G.
[4
]
Kaanders, Johannes H. A. M.
[1
]
机构:
[1] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Maxillofacial Surg, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词:
F-18-fluorothymidine PET;
proliferation;
head and neck cancer;
immunohistochemistry;
iododeoxyuridine;
thymidine kinase;
CYTOSOLIC THYMIDINE KINASE;
F-18-FLT PET;
NECK-CANCER;
IMAGING PROLIFERATION;
NUCLEAR ANTIGEN;
IN-VIVO;
RADIOTHERAPY;
HEAD;
REPOPULATION;
THERAPY;
D O I:
10.2967/jnumed.109.071910
中图分类号:
R8 [特种医学];
R445 [影像诊断学];
学科分类号:
1002 ;
100207 ;
1009 ;
摘要:
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of F-18-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate F-18-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Methods: Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an F-18-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. F-18-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUVmean] and maximum standardized uptake value [SUVmax]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was visually and semiquantitatively assessed. Results: All primary tumors were identified with F-18-FLT PET but with a large range in tracer uptake (mean SUVmax, 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUVmean and SUVmax, but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor F-18-FLT uptake. Conclusion: The current study demonstrated only a weak correlation between F-18-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
引用
收藏
页码:713 / 719
页数:7
相关论文